• Guo-cheng Zhong, Bin Yan, Yi Sun, Xiao-yu Zhang, Jian Chen, Yi Su, Hao-ping Sun, and Bo Zhu.
• Center of Oncology and Hematology, 452nd Hospital of People's Liberation Army (PLA), Chengdu 610021, China. zgc005@yahoo.com
• Zhonghua Xue Ye Xue Za Zhi. 2012 Dec 1; 33 (12): 1000-3.

ObjectiveThis research was aimed to evaluate the immune mechanism and clinical effect of immunotherapy of dendritic cells (DC) and cytokine-induced killer cell (CIK) combined with chemotherapy on multiple myeloma (MM).Methods60 patients with MM were randomly divided into two groups. 30 patients in chemotherapy group were treated by chemotherapy only, 30 patients in joint group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy. A variety of immunological indexes (Hsp70, Th1/Th2, TGF-β) of all patients before and after chemotherapy were recorded; Also the clinical outcomes between two groups were compared.ResultsAfter chemotherapy, the immunological indexes of all patients were better than those of before chemotherapy (P < 0.05); After treatment, quality of life, clinical index and survival in joint group were better than in chemotherapy group (P < 0.05).ConclusionChemotherapy could break the immunosuppression of MM and improve the anti-tumor response of DC-CIK; Chemotherapy and DC-CIK may have synergistic effect for MM.

18 keywords...

hide…